CRLCharles River Laboratories International Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

James C. Foster

Location

Massachusetts, USA

Exchange

NYSE

Website

https://criver.com

Summary

Charles River Laboratories International, Inc.

Company Info

CEO

James C. Foster

Location

Massachusetts, USA

Exchange

NYSE

Website

https://criver.com

Summary

Charles River Laboratories International, Inc.

AI Insights for CRL
6 min read

Quick Summary

Charles River Laboratories International, Inc. is a contract research and manufacturing support company serving the life sciences, biotechnology, pharmaceutical, academic, and government research markets. The company helps customers move drug candidates from early discovery through non-clinical development and safety assessment, with a strong emphasis on research models, testing services, and specialized laboratory capabilities. Its Research Models and Services business supplies rodent models, purpose-bred rats and mice, and related services that researchers use in preclinical experiments. Its Discovery and Safety Assessment business provides target validation, compound screening, antibody discovery, in vivo discovery, toxicology, and safety testing services for drug developers. Its Manufacturing Solutions business supports pharmaceutical, biologics, medical device, and consumer product companies with microbial testing, biologics testing, and quality-control services. The company’s main customers are large pharmaceutical companies, emerging biotechnology firms, academic institutions, government laboratories, and other organizations that need outsourced research, development, and regulated testing capacity.

Strengths

•

Charles River has a strong market position in preclinical drug development services and research models.

•

The company has deep scientific expertise, a broad customer base, and long-standing relationships with pharmaceutical, biotechnology, academic, and government research organizations.

•

Its portfolio spans research models, discovery services, safety assessment, biologics testing, microbial testing, and manufacturing-support services, which gives customers the ability to outsource multiple steps to one provider.

•

The company also benefits from specialized infrastructure, regulatory know-how, and technical capabilities that are difficult for smaller competitors to replicate.

•

Its Apollo for CRADL platform suggests that management is investing in digital tools that could improve customer experience and operational efficiency.

Key Risks

•

The most visible risk is regulatory change, especially the FDA’s move to phase out some animal testing requirements and encourage AI and other human-relevant methods in drug development.

•

This could pressure the long-term growth outlook for research models and certain preclinical services if customers materially reduce animal study volumes.

•

Macroeconomic risks also matter because tariffs, inflation, interest rates, and market volatility can affect customer budgets and investor risk appetite.

•

Biotechnology funding weakness could reduce early-stage discovery projects, delay safety assessment work, and pressure utilization rates.

What to Watch

During the most recent period described in the data, Charles River reported operating revenue of about $1.004 billion and total gross profit of about $363.4 million.
The company generated total operating income of about $119.9 million, but net income was slightly negative at approximately $0.76 million, which produced basic and diluted EPS of negative $0.03.
News during the period highlighted the launch of Apollo for CRADL, a secure cloud platform designed to help vivarium rental clients access training, ordering, data, and study support tools.
The market reacted positively to the Apollo announcement, with shares rising 3.8% after the news according to the provided headlines.
Earlier reporting also showed a strong Q2 2025 earnings beat, with revenue exceeding estimates and EPS rising meaningfully from the prior year.
At the same time, the company continued to face investor debate about the long-term impact of FDA policy changes that encourage alternatives to animal testing.

Price Drivers

•

CRL’s stock price is being driven by a mix of earnings performance, regulatory expectations, life sciences funding conditions, and investor sentiment toward animal-based preclinical research.

•

The Q2 2025 news showed revenue of about $1.03 billion, modest year-over-year growth, and adjusted EPS that beat consensus by a wide margin, which supported a positive stock reaction.

•

However, the fundamental snapshot shows Q3 2026 reported EPS near breakeven or slightly negative, with net income of negative $0.76 million, which may raise concerns about profitability volatility.

•

The market has also reacted sharply to the FDA’s stated intention to reduce animal testing requirements and encourage AI and other human-relevant methods, because this directly affects perceived long-term demand for research models and some preclinical services.

•

Valuation is another driver, with metrics such as EV to EBITDA and EV to free cash flow appearing elevated, making the stock sensitive to earnings disappointments or changes in growth expectations.

•

Broader market conditions, including tariff headlines, risk appetite, biotechnology funding cycles, and demand for outsourced drug development services, can also move the shares.

Recent News

•

Recent company-specific news includes the launch of Apollo for CRADL, a secure cloud platform designed for vivarium rental clients.

•

The platform provides tools for training, ordering, data access, and study support, with the goal of helping researchers start studies faster and improve drug development efficiency.

•

Shares reportedly rose 3.8% after the announcement, suggesting investors viewed the digital initiative positively.

•

Charles River also reported a strong Q2 2025 result, with revenue of $1.03 billion, year-over-year growth of 0.6%, and EPS of $3.12 that beat consensus estimates by 24.8%.

•

Segment revenue reportedly exceeded expectations across several businesses, although corporate overhead was higher and Manufacturing Solutions operating income missed expectations.

•

Another major news item was the sharp stock decline following the FDA’s move to reduce animal testing requirements, which raised concerns about the durability of demand for some of Charles River’s core services.

Market Trends

•

The life sciences outsourcing market continues to be shaped by pharmaceutical productivity pressures, biotechnology funding cycles, and the desire to convert fixed research costs into variable outsourced spending.

•

Large drug developers still need discovery, safety assessment, biologics testing, and manufacturing-support services, but they are increasingly selective about budgets and vendor performance.

•

A major trend affecting Charles River is the regulatory and scientific movement toward alternatives to animal testing, including AI models, organoids, organ-on-chip systems, computational toxicology, and other human-relevant methods.

•

This trend creates risk for traditional research models but also creates an opportunity for service providers that can adapt and validate new approaches.

•

Broader equity-market valuation concerns, tariff headlines, and changing investor appetite for healthcare and life sciences stocks can amplify share-price volatility.

•

Demand for biologics, complex therapies, and regulated quality testing remains a supportive trend for the Manufacturing Solutions side of the business.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on CRL

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show